Search

Displaying results 1861 - 1870 of 5419 in total
  1. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. … Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.

  2. Drug

    Pancrelipase

    go.drugbank.com/drugs/DB00085
    ApprovedInvestigational

    [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

  3. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function. … More specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act. … [A14416] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery.

  5. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

    Categories: Antiinfectives for Systemic Use
  6. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

  7. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846]. … Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant

  8. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).

  9. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  10. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production. … Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity.